← Back to directory

Daniil Stroyakovskiy

Researcher Next ID · RN-009634

Researcher · Medicine

CI2

, Czechia

Not currently recruitingFunding unknown
Works count
216
Citation count
25,029
H-index
49
i10-index
83

Research interests

Medicine
Biochemistry, Genetics and Molecular Biology
HER2/EGFR in Cancer Research
Melanoma and MAPK Pathways
Cancer Immunotherapy and Biomarkers
Colorectal Cancer Treatments and Studies
Lung Cancer Treatments and Mutations

Publications

  • Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

    New England Journal of Medicine · 2019 · 10.1056/nejmoa1904059

  • Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

    New England Journal of Medicine · 2018 · 10.1056/nejmoa1716948

  • Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    The Lancet · 2015 · 10.1016/s0140-6736(15)60898-4

  • Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma

    New England Journal of Medicine · 2014 · 10.1056/nejmoa1408868

  • Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    New England Journal of Medicine · 2014 · 10.1056/nejmoa1406037

Current projects

    No projects listed.